Natco Pharma

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and Agro chemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs. The company specialises in producing complex medicines at affordable prices. NATCO is a science driven company and focuses on limited competition molecules in the US.

History

 * NATCO Pharma was founded in the year 1981 by V C Nannapaneni
 * In 1983 operations commenced at manufacturing facility at Nagarjunasagar, Telangana
 * In 1986 Chemical division commenced at Mekaguda, Telangana
 * In 2008, NATCO Pharma filed its first paragraph IV filing in the US with the USFDA,
 * In 2012, NATCO Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.
 * In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.
 * In 2016, NATCO Pharma launched the first Tamiflu capsule in the US market.
 * In 2019, NATCO Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.
 * In 2022 Crop Health Sciences division launched Chlorantraniliprole (CTPR) based products.
 * NATCO launched the first generic version of Revlimid in the US market
 * For the financial Year 2024, NATCO recorded its highest ever revenue, Earnings Before Interests Tax Depreciation and Amortization and profit after tax.